Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

217 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
An ultrapure plasma-derived monoclonal antibody-purified factor IX concentrate (Nonafact®), results of phase III and IV clinical studies.
Mauser-Bunschoten EP, Kleine Budde I, Lopaciuk S, Koopman MM, Van Der Meer FJ, Novàkovà IR, Ypma P, Van Der Linden PW, Windyga J, Strengers PF. Mauser-Bunschoten EP, et al. Among authors: van der meer fj, van der linden pw. Haemophilia. 2011 May;17(3):439-45. doi: 10.1111/j.1365-2516.2010.02453.x. Epub 2011 Mar 1. Haemophilia. 2011. PMID: 21362109 Clinical Trial.
Perioperative replacement therapy in haemophilia B: An appeal to "B" more precise.
Hazendonk HCAM, Preijers T, Liesner R, Chowdary P, Hart D, Keeling D, Driessens MHE, Laros-van Gorkom BAP, van der Meer FJM, Meijer K, Fijnvandraat K, Leebeek FWG, Mathôt RAA, Collins PW, Cnossen MH. Hazendonk HCAM, et al. Haemophilia. 2018 Jul;24(4):611-618. doi: 10.1111/hae.13469. Epub 2018 Apr 29. Haemophilia. 2018. PMID: 29707861 Free article.
Facilitating the implementation of pharmacokinetic-guided dosing of prophylaxis in haemophilia care by discrete choice experiment.
Lock J, de Bekker-Grob EW, Urhan G, Peters M, Meijer K, Brons P, van der Meer FJ, Driessens MH, Collins PW, Fijnvandraat K, Leebeek FW, Cnossen MH; ‘OPTI-CLOT’ study group. Lock J, et al. Among authors: van der meer fj. Haemophilia. 2016 Jan;22(1):e1-e10. doi: 10.1111/hae.12851. Epub 2015 Nov 27. Haemophilia. 2016. PMID: 26612493
Is pharmacokinetic-guided dosing of desmopressin and von Willebrand factor-containing concentrates in individuals with von Willebrand disease or low von Willebrand factor reliable and feasible? A protocol for a multicentre, non-randomised, open label cohort trial, the OPTI-CLOT: to WiN study.
Heijdra JM, Al Arashi W, de Jager NCB, Cloesmeijer ME, Bukkems LH, Zwaan CM, Leebeek FWG, Mathôt RAA, Cnossen MH; OPTI-CLOT Study Group. Heijdra JM, et al. BMJ Open. 2022 Feb 15;12(2):e049493. doi: 10.1136/bmjopen-2021-049493. BMJ Open. 2022. PMID: 35168962 Free PMC article.
Population pharmacokinetics of factor IX in hemophilia B patients undergoing surgery.
Preijers T, Hazendonk HCAM, Liesner R, Chowdary P, Driessens MHE, Hart D, Keeling D, Laros-van Gorkom BAP, van der Meer FJM, Meijer K, Fijnvandraat K, Leebeek FWG, Collins PW, Cnossen MH, Mathôt RAA; OPTI‐CLOT study group. Preijers T, et al. J Thromb Haemost. 2018 Nov;16(11):2196-2207. doi: 10.1111/jth.14292. Epub 2018 Oct 28. J Thromb Haemost. 2018. PMID: 30394056 Free article.
Desmopressin testing in von Willebrand disease: Lowering the burden.
Heijdra JM, Atiq F, Al Arashi W, Kieboom Q, Wuijster E, Meijer K, Kruip MJHA, Leebeek FWG, Cnossen MH; OPTI‐CLOT Study Group. Heijdra JM, et al. Res Pract Thromb Haemost. 2022 Sep 26;6(6):e12784. doi: 10.1002/rth2.12784. eCollection 2022 Aug. Res Pract Thromb Haemost. 2022. PMID: 36186107 Free PMC article.
217 results